Up 40%: Is This Red-Hot Growth Stock Still a Buy?
28/4 14:30
Last Friday, Agenus (NASDAQ: AGEN), an immuno-oncology player, saw its shares soar by a staggering 40.8%. This remarkable rally occurred seemingly without a clear catalyst. The company is set to announce its first-quarter earnings for 2024 before the market opens on Tuesday, May...